Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and TherapyGlobeNewsWire · 6 days ago
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin SyndromeGlobeNewsWire · Oct 14, 2026
Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and TherapyGlobeNewsWire · Oct 6, 2026
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin SyndromeGlobeNewsWire · Sep 22, 2026
Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah's Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICUGlobeNewsWire · Sep 10, 2026
CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin SyndromeGlobeNewsWire · Sep 8, 2026Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$1.83 | -$1.90 | Miss |
| May 7, 2026 | -$1.80 | -$1.77 | Beat |
| Mar 26, 2026 | -$6.42 | -$14.80 | Miss |
| Nov 6, 2025 | -$6.36 | -$6.71 | Miss |
| Aug 7, 2025 | -$6.83 | -$6.28 | Beat |
| May 13, 2025 | -$3.85 | -$6.50 | Miss |